Comgest Global Investors S.A.S. Has $5.32 Million Position in Biogen Inc. (BIIB)

Comgest Global Investors S.A.S. grew its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 shares of the biotechnology company’s stock after acquiring an additional 800 shares during the period. Comgest Global Investors S.A.S.’s holdings in Biogen were worth $5,323,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. grew its holdings in Biogen by 2.3% during the 2nd quarter. BlackRock Inc. now owns 18,107,358 shares of the biotechnology company’s stock worth $4,913,612,000 after acquiring an additional 415,099 shares in the last quarter. Vanguard Group Inc. grew its holdings in Biogen by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 14,534,827 shares of the biotechnology company’s stock worth $3,944,171,000 after acquiring an additional 182,337 shares in the last quarter. State Street Corp grew its holdings in Biogen by 1.5% during the 2nd quarter. State Street Corp now owns 9,721,312 shares of the biotechnology company’s stock worth $2,637,973,000 after acquiring an additional 140,929 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Biogen by 4.0% during the 1st quarter. Clearbridge Investments LLC now owns 9,121,025 shares of the biotechnology company’s stock worth $2,493,871,000 after acquiring an additional 351,224 shares in the last quarter. Finally, FMR LLC grew its holdings in Biogen by 10.1% during the 2nd quarter. FMR LLC now owns 6,104,026 shares of the biotechnology company’s stock worth $1,656,390,000 after acquiring an additional 561,436 shares in the last quarter. 88.35% of the stock is owned by institutional investors.

Biogen Inc. (NASDAQ BIIB) traded up $0.83 during midday trading on Wednesday, hitting $310.52. 547,315 shares of the company were exchanged, compared to its average volume of 1,516,820. The company has a market cap of $65,790.00, a P/E ratio of 14.62, a P/E/G ratio of 1.97 and a beta of 0.72. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90. Biogen Inc. has a twelve month low of $244.28 and a twelve month high of $348.84.

Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.70 by $0.61. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $5.19 earnings per share. analysts forecast that Biogen Inc. will post 22.03 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Comgest Global Investors S.A.S. Has $5.32 Million Position in Biogen Inc. (BIIB)” was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/11/15/comgest-global-investors-s-a-s-has-5-32-million-position-in-biogen-inc-biib.html.

BIIB has been the subject of several recent analyst reports. BMO Capital Markets reissued a “hold” rating and set a $318.00 price objective on shares of Biogen in a report on Tuesday, July 18th. Goldman Sachs Group, Inc. (The) raised shares of Biogen from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $228.00 to $338.00 in a report on Wednesday, July 26th. Leerink Swann reissued a “market perform” rating and set a $338.00 price objective (up from $304.00) on shares of Biogen in a report on Wednesday, July 26th. Deutsche Bank AG reissued a “buy” rating and set a $319.00 price objective (up from $315.00) on shares of Biogen in a report on Wednesday, July 26th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $311.00 price objective (up from $301.00) on shares of Biogen in a report on Wednesday, July 26th. Twelve analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $341.89.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply